| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/03/2005 | US20050026893 Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants |
| 02/03/2005 | US20050026892 Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application |
| 02/03/2005 | US20050026891 Progesterone receptor modulators with increased antigonadotropic activity for female birth control and hormone replacement therapy |
| 02/03/2005 | US20050026890 Such as loratadine, cetirizine, or fexofenadine; low amounts of active agents, less prone to detrimental side effects; reducing levels of, or sensitivity to, adenosine or adenosine receptors |
| 02/03/2005 | US20050026889 Treating acne, seborrhea, hirsutism, alopecia, mastodynia, prostate hyperplasia and carcinoma, virilization syndromes in the female, early puberty, use in inhibition of sexual aggressiveness in the male, male contraception |
| 02/03/2005 | US20050026888 Formulation containing anti-inflammatory androstane derivatives |
| 02/03/2005 | US20050026887 Anticholinergic is a 1-(3-phenoxypropyl)-3-((2-hydroxy-2,2-bisthien-2-yl)acetoxy)quinuclidinium salt of given formula and steroid such as fluticasone; kit with dosage forms and instructions; treating allergic or non-allergic rhinitis |
| 02/03/2005 | US20050026886 Phosphodiesterase IV (PDE IV) inhibitor such as roflumilast or cilomilast with a 1-(3-phenoxypropyl)-3-((2-hydroxy-2,2-bisthien-2-yl)acetoxy)quinuclidinium salt of given formula; kit with dosage forms and instructions; treating inflammatory or obstructive respiratory diseases |
| 02/03/2005 | US20050026885 Administering during follicular phase in a dosage less than an ovulation-inhibiting or abortion-inductive dose; 11 beta -[(4-N,N-Dimethylamino) -phenyl]-17 beta -hydroxy-17 alpha -propinyl-4,9(10)-estradien-3-one (RU 38486) for example; will not abort previously implanted fetus |
| 02/03/2005 | US20050026884 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| 02/03/2005 | US20050026883 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 02/03/2005 | US20050026882 Such as montelukast, zafirlukast or pranlukast; low amounts of active agents, less prone to detrimental side effects |
| 02/03/2005 | US20050026881 Immunoglobulin E (IgE); antibody such as omalizumab; low amounts of active agents, less prone to detrimental side effects |
| 02/03/2005 | US20050026879 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 02/03/2005 | US20050026878 Steroid modulators in the treatment of peripheral nerve sheath tumors |
| 02/03/2005 | US20050026877 Pharmaceutical compositions comprising active vitamin D compounds |
| 02/03/2005 | US20050026876 9-aminomethyl substituted minocycline compounds |
| 02/03/2005 | US20050026875 Treating bacterial, viral, or fungal infections, cancer, a lung injury, an eye disorder, neurological disorder or stroke |
| 02/03/2005 | US20050026874 Method of use of the compound that includes a conjugated polyene with between 7 to 14 double bonds, and cyclohexene rings with ether, phosphate, sulfate, dextran or other group which imparts water solubility |
| 02/03/2005 | US20050026873 Type-I methionyl aminopeptidases inhibitors in antibacterial targeting |
| 02/03/2005 | US20050026872 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor |
| 02/03/2005 | US20050026871 Such as calcitriol, before bisphosphonates such as alendronate, risedronate, etidronate, zoledronate, and tiludronate |
| 02/03/2005 | US20050026870 Use of bisphosphonates for the treatment of osteogenesis imperfecta |
| 02/03/2005 | US20050026869 Process for controlling crystal structure of risedronate |
| 02/03/2005 | US20050026868 Phosphorus-containing macrocycles |
| 02/03/2005 | US20050026867 Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain |
| 02/03/2005 | US20050026866 Detecting or treating mammalian tumor cells; tissue-targeted therapy; genetic engineered Bordetella pertussis; biodrugs |
| 02/03/2005 | US20050026865 Feeds contains alginate and an acceptable carriers; nutrients; weight gain |
| 02/03/2005 | US20050026864 Bisphosphonate conjugates and methods of making and using the same |
| 02/03/2005 | US20050026861 Modified dinucleotides for reduce or improve immunostimulatory; genetic vaccines; cancer vaccines |
| 02/03/2005 | US20050026859 Methods and compositions of gene delivery agents for systemic and local therapy |
| 02/03/2005 | US20050026858 Modified nucleotides for immunotherapy; induce immunology response; consisting of nucleoside methylphosphonate and 2'-O-methyl-ribonucleoside groups |
| 02/03/2005 | US20050026853 Anti-viral 7-deaza D-nucleosides and uses thereof |
| 02/03/2005 | US20050026852 Reducing the toxicity side effect of anticarcinogenic agent, including a selenium compound selecting from seleno-L-methionine or methylselenocysteine; administering before, during or after administration of chemotherapeutic drug |
| 02/03/2005 | US20050026851 Single dose fast dissolving azithromycin |
| 02/03/2005 | US20050026850 Metered dose inhalers; low amounts of active agents, less prone to detrimental side effects |
| 02/03/2005 | US20050026849 Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases |
| 02/03/2005 | US20050026848 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease |
| 02/03/2005 | US20050026847 Treating phagocytosis with sea whip extracts, a diterpene glycosides; antiinflammatory, antiproliferative agents |
| 02/03/2005 | US20050026846 Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism |
| 02/03/2005 | US20050026844 Inhibitors for the soluble epoxide hydrolase |
| 02/03/2005 | US20050026842 To separate the brain-derived wanting of the opioid from the analgesic or anti-diarrhea, loose stool effect of the opioid; synergistic; simultaneously not allowing for increased dopamine in regions of the brain that would effect wanting of the opiod |
| 02/03/2005 | US20050026835 Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators |
| 02/03/2005 | US20050026819 Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent |
| 02/03/2005 | US20050026814 Diagnosis and treatment of human kidney diseases |
| 02/03/2005 | US20050026813 Antibiotic-metal complexes in the detection of gram-positive bacteria and other biological analytes |
| 02/03/2005 | US20050026811 antagonists for the receptor for advanced glycated endproducts(RAGE), used for treatment of Alzheimer's disease |
| 02/03/2005 | US20050026305 Aminodextran compositions and conjugates and method of making and using them |
| 02/03/2005 | US20050026283 Using electric field modification to transfer components across cell barriers; organelle transfer; in vitro fertility |
| 02/03/2005 | US20050026278 RNA interference mediating small RNA molecules |
| 02/03/2005 | US20050026251 Netrin receptor protein for use in identification of modulator for use in treatment and prevention of infection, nervous system, autoimmune, inflammatory, psycological and reproductive disorders |
| 02/03/2005 | US20050026245 Use of cpg oligodeoxynucleotides to induce angiogenesis |
| 02/03/2005 | US20050026223 Identifying modulators which bind hormone receptors, enhance bone characteristics and treat bone disorders |
| 02/03/2005 | US20050026187 Methods of and compounds for modulating the activity of bacterial FabG |
| 02/03/2005 | US20050026143 Synthesis of biologically active compounds in cells |
| 02/03/2005 | US20050025847 For preventing sexually transmitted disease (STD) infections which includes bisabolol; STDs such as HIV, herpes, gonorrhea, chlamydia, syphilis, and trichomoniasis |
| 02/03/2005 | US20050025846 Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same |
| 02/03/2005 | US20050025844 Weight control compositions and methods |
| 02/03/2005 | US20050025841 Therapeutic methods using herbal compositions |
| 02/03/2005 | US20050025840 Compositions and methods directed towards sore muscles and joints |
| 02/03/2005 | US20050025839 Formulation approach to enhance transporter-mediated drug uptake |
| 02/03/2005 | US20050025834 Includes an inner core of a biocompatible solid and biocompatible fluids with drug dispersed, suspended or dissolved therein, and a polymer layer covering less than 100% of the core; biocompatible solid is less soluble in physiological fluid than in the biocompatible fluid |
| 02/03/2005 | US20050025833 Pharmaceutical composition and method for transdermal drug delivery |
| 02/03/2005 | US20050025832 Methods and devices for providing prolonged drug therapy |
| 02/03/2005 | US20050025831 Release drug within the gastrointestinal tract at an ascending release rate over an extended time period; osmotic dosage form with semipermeable membrane; initial dose of drug supplied in an immediate-release overcoat; for treating hyperactivity/attention deficit with methylphenidate for example |
| 02/03/2005 | US20050025828 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| 02/03/2005 | US20050025827 Pharmaceutical formulation for contraception and hormone-replacement therapy |
| 02/03/2005 | US20050025825 Oral dosage form which releases the drug in the small intestine for side effect reduction of nausea, vomiting, diarrhea, constipation, cramping, and bloating; improve patient compliance in treating menorrhagia |
| 02/03/2005 | US20050025818 Transdermal warfarin system |
| 02/03/2005 | US20050025817 Skin drug delivery system with pads and liquids with insoluble drugs |
| 02/03/2005 | US20050025815 Protonated/acidified nucleic acids are effective as bactericidal and/or bacteriostatic agents |
| 02/03/2005 | US20050025810 Treatment of ocular disease |
| 02/03/2005 | US20050025807 Cured porous calcium phosphate material and uses thereof |
| 02/03/2005 | US20050025806 A silicone support of methylvinylsiloxane polymer including a fumed silca reinforcement filler; growth and/or reproduction-associated drug, derivative or analogue and carrier; each implant of insufficient size and/or payload for the predetermined threshold blood level of indicated drug; high-speed |
| 02/03/2005 | US20050025805 Compounds of polyvinylpyridine oxide for treatment of nervous system disorders, liver disorders amotropic lateral sclerosis disease and graftingfor antiinflammatory agents |
| 02/03/2005 | US20050025804 Reduction of adverse inflammation |
| 02/03/2005 | US20050025792 Amphiphilic surfactant with hydrophilic character that is a glyceride polyoxyethylene glycol and saturated fatty acids; or polyoxyethylated hydrogenated castor oil (Cremophor") |
| 02/03/2005 | US20050025791 Pharmaceutical compositions with improved dissolution |
| 02/03/2005 | US20050025774 Such as N-(2-ethoxybenzyl)-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide; for preventing, treating or delaying AIDS |
| 02/03/2005 | US20050025765 Antagonist is selected from an antioxidant or an inhibitor of a pro-inflammatory interleukin, TNF- alpha synthesis, membrane-bound TNF- alpha, a natural receptor of TNF- alpha, nitric oxide synthase, phospholipase A2, apoptosis, matrix metalloproteases, or p38 kinase |
| 02/03/2005 | US20050025762 Methods of diagnosing and treating pre-eclampsia or eclampsia |
| 02/03/2005 | US20050025757 Oxygen carrier system, artificial oxygen carrier, and reducing agent |
| 02/03/2005 | US20050025756 Combination with a solvent, skin buffer and antioxidant to improve solubility and bioavailability for a variety of dosage forms |
| 02/03/2005 | US20050025751 Increased or reduced expression of tumor necrosis factors or interleukins; antiinflammatory agents; autoimmune diseases |
| 02/03/2005 | US20050025748 Delivery of compounds with rehydrated blood cells |
| 02/03/2005 | US20050025741 Poly and copoly(N-vinylamide)s and their use in capillary electrophoresis |
| 02/03/2005 | US20050025740 Polyoxime compounds and their preparation |
| 02/03/2005 | US20050025737 Compositions containing melon extracts |
| 02/03/2005 | US20050025734 Lactacystin, a peptidyl aldehyde, or a peptidyl epoxy ketone inhibits proteasomal activity; epidermal growth factor, a fibroblast growth factor, a platelet-derived growth factor, a transforming growth factor, a parathyroid hormone, etc for promoting skin tissue growth, an excipient |
| 02/03/2005 | US20050025723 Topical formulation containing melanocyte stimulating hormone and/or derivative in carrier |
| 02/03/2005 | US20050025718 Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| 02/03/2005 | US20050025717 Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
| 02/03/2005 | US20050025716 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
| 02/03/2005 | US20050025715 Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
| 02/03/2005 | US20050025714 Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
| 02/03/2005 | US20050025713 Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
| 02/03/2005 | US20050025712 Transmucosal absorption through oral mucosa to systemic circulatory system; bioavailability, rapid onset; active ingredient, solvent and low molecular weight hydrocarbon propellant |
| 02/03/2005 | US20050023507 pi-electron donor group bonded to a pi-electron conjugated bridge group bonded to a mono- or dicyanodihydrofuran acceptor; large hyperpolarizability, dipole moment, and electrooptic coefficients; electrooptics |
| 02/03/2005 | DE202004009689U1 Combating stress states or nervous system or metabolic disorders, using glycine as neurotransmission modulator showing antistress, stress protective, nootropic and toxin binding actions |
| 02/03/2005 | DE10360086A1 Ambroxolhaltige Tabletten Ambroxol tablets |